The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRINOX in first-line metastatic pancreatic cancer regimen (FLMPC): What profile of patients take a real advantage? Real world cohort from cancer observatory from Brittany and Pays de la Loire areas.
Jean-Philippe Metges
No relevant relationships to disclose
Jean François Ramée
No relevant relationships to disclose
Roger Faroux
No relevant relationships to disclose
Jean-Yves Douillard
No relevant relationships to disclose
Marc Porneuf
No relevant relationships to disclose
Isabelle Cumin
No relevant relationships to disclose
Pierre-Luc Etienne
No relevant relationships to disclose
Alain Gourlaouen
No relevant relationships to disclose
Guillaume Geslin
No relevant relationships to disclose
Nacredine Achour
No relevant relationships to disclose
Patrick Soulie
No relevant relationships to disclose
Gerard Le Bihan
No relevant relationships to disclose
Catherine Le Roux
No relevant relationships to disclose
Laurent Miglianico
No relevant relationships to disclose
Philippe Deguiral
No relevant relationships to disclose
Christian Riche
No relevant relationships to disclose
Fanny Marhuenda
No relevant relationships to disclose
Delphine Deniel Lagadec
No relevant relationships to disclose
Loic Campion
No relevant relationships to disclose
Francoise Grude
No relevant relationships to disclose